Comprehensive Analysis of Ebola Virus GP1 in Viral Entry
Overview
Affiliations
Ebola virus infection is initiated by interactions between the viral glycoprotein GP1 and its cognate receptor(s), but little is known about the structure and function of GP1 in viral entry, partly due to the concern about safety when working with the live Ebola virus and the difficulty of manipulating the RNA genome of Ebola virus. In this study, we have used a human immunodeficiency virus-based pseudotyped virus as a surrogate system to dissect the role of Ebola virus GP1 in viral entry. Analysis of more than 100 deletion and amino acid substitution mutants of GP1 with respect to protein expression, processing, viral incorporation, and viral entry has allowed us to map the region of GP1 responsible for viral entry to the N-terminal 150 residues. Furthermore, six amino acids in this region have been identified as critical residues for early events in Ebola virus entry, and among these, three are clustered and are implicated as part of a potential receptor-binding pocket. In addition, substitutions of some 30 residues in GP1 are shown to adversely affect GP1 expression, processing, and viral incorporation, suggesting that these residues are involved in the proper folding and/or overall conformation of GP. Sequence comparison of the GP1 proteins suggests that the majority of the critical residues for GP folding and viral entry identified in Ebola virus GP1 are conserved in Marburg virus. These results provide information for elucidating the structural and functional roles of the filoviral glycoproteins and for developing potential therapeutics to block viral entry.
Identification of Filovirus Entry Inhibitors from Marine Fungus-Derived Indole Alkaloids.
Wang L, Seravalli J, Eaton B, Liu Y, Holbrook M, Lan W Mar Drugs. 2025; 23(1).
PMID: 39852525 PMC: 11766795. DOI: 10.3390/md23010023.
N-Substituted Pyrrole-Based Heterocycles as Broad-Spectrum Filoviral Entry Inhibitors.
Durante D, Bott R, Cooper L, Owen C, Morsheimer K, Patten J J Med Chem. 2024; 67(16):13737-13764.
PMID: 39169825 PMC: 11812679. DOI: 10.1021/acs.jmedchem.4c00527.
Recent Advances in Therapeutic Approaches Against Ebola Virus Infection.
Soni M, Tulsian K, Barot P, Vyas V Recent Adv Antiinfect Drug Discov. 2024; 19(4):276-299.
PMID: 38279760 DOI: 10.2174/0127724344267452231206061944.
Jain A, Govindan R, Berkman A, Luban J, Diaz-Salinas M, Durham N PLoS Pathog. 2023; 19(12):e1011848.
PMID: 38055723 PMC: 10727438. DOI: 10.1371/journal.ppat.1011848.
Pseudotyped Viruses for Marburgvirus and Ebolavirus.
Zhang L, Liu S, Wang Y Adv Exp Med Biol. 2023; 1407:105-132.
PMID: 36920694 DOI: 10.1007/978-981-99-0113-5_6.